Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.
—
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.
—
Daily adjusted close
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.